← Eichor
Study identifier: NCT05444348 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)

Condition: Multiple Myeloma · Myelodysplastic Syndromes · Lymphoma  ·  Sponsor: Christoffer Johansen

PhaseNA
Planned participants920
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Patients diagnosed with hematologic cancer are at substantial risk of dying, as 5-year survival among patients with acute myeloid leukemia is 20 % and only every second patient treated for incurable myeloma lives 5 years after date of diagnosis. Nevertheless, many overestimate their prognosis, and value of therapy. Patients with hematological cancers frequently have poor end of life outcomes, such as high treatment activity close to death, where clinical effects are doubtful, and low utilization of palliative care. Prognostic awareness and end of life (EOL) issues have urgency in the communication between patients, their caregiving relatives, and clinicians, in order to avoid futile treatments and suffering at EOL. Inspired by advanced care planning, the investigators developed the concept "Advance Consultations Concerning participants Life and Treatment" (ACT) in collaboration with a group consisting of hematologists, nurses, patients, and caregivers. The ACT concept consists of an 8-hour training day for clinicians, clinical tools, system changes, and preparation material for patients and caregivers prior to the consultation. ACT involves patients and caregivers earlier in preparation for life with chronic progressive disease and EOL-decisions, through an intervention based on compassionate communication and early planning of EOL-care. The aim of the study is to investigate the effect of the intervention on use of chemotherapy and quality of EOL-care in patients with hemato…

This description comes directly from the study's public registry record.

Talk to the study team

Cæcilie Borregaard Myrhøj, MScN  ·  +45 60701620  ·  caecilie.borregaard.myrhoej@regionh.dk

Annika von Heymann, PhD  ·  +45 21310881  ·  annika.von.heymann@regionh.dk

Always discuss trial participation with your own doctor first.

Locations (7)

Aalborg UniversitetshospitalAalborg, DenmarkRecruiting
Aarhus UniversitetshospitalAarhus, DenmarkRecruiting
Sydvestjysk sygehus - EsbjergEsbjerg, DenmarkRecruiting
Regionshospitalet GødstrupHerning, DenmarkRecruiting
Odense UniversitetshospitalOdense, DenmarkRecruiting
Sjællands universitetshospital RoskildeRoskilde, DenmarkRecruiting
Lillebælt syge - Vejle SygehusVejle, DenmarkRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05444348